Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression

Behavioural Pharmacology

Volumn 25, Issue 5-6, 2014, Pages 567-574

  Papp, Mariusz ^a   Gruca, Piotr ^a   Lason Tyburkiewicz, Magdalena ^a   Adham, Nika ^b   Kiss, Béla ^c   Gyertyan, Istvan ^c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b FOREST RESEARCH INSTITUTE   (United States)

^c GEDEON RICHTER LTD   (Hungary)

Author keywords

anhedonia; antipsychotic agents; bipolar disorder; cariprazine; chronic mild stress; depression; dopamine D3 receptor; dopamine receptor partial agonist; negative symptoms; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CARIPRAZINE; DOPAMINE 3 RECEPTOR; IMIPRAMINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; SUGAR INTAKE;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; LOW DRUG DOSE; MALE; NEGATIVE SYNDROME; NONHUMAN; RAT; SUGAR INTAKE; ADMINISTRATION AND DOSAGE; ANIMAL; CHRONIC DISEASE; COMPARATIVE STUDY; DEPRESSIVE DISORDER; DISEASE MODEL; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG EFFECTS; MENTAL STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANHEDONIA; ANIMALS; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; DEPRESSIVE DISORDER; DIETARY SUCROSE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING BEHAVIOR; IMIPRAMINE; MALE; PIPERAZINES; QUINOLONES; RATS, WISTAR; STRESS, PSYCHOLOGICAL;

EID: 84906057004     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000070     Document Type: Article

References (56)

1. Adham N, Gyertyán I, Kiss B (2013). At antipsychotic-like effective doses, cariprazine displays potent dopamine D3 and D2 receptor occupancy in vivo and efficacy across animal models. 166th Annual Meeting of the American Psychiatric Association. San Francisco, CA: American Psychiatric Association.
2. Andreasen NC (1982). Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784-788.
3. Andreasen NC, Olsen S (1982). Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39:789-794.
4. Carpenter WT Jr, Heinrichs DW, Wagman AM (1988). Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 145:578-583.
5. Chapman LJ, Chapman JP, Raulin ML (1976). Scales for physical and social anhedonia. J Abnorm Psychol 85:374-382.
6. Citrome L (2013). Cariprazine in bipolar disorder: Clinical efficacy, tolerability, and place in therapy. Adv Ther 30:102-113.
7. Citrome L (2013). Cariprazine in schizophrenia: Clinical efficacy, tolerability, and place in therapy. Adv Ther 30:114-126.
8. DeLeon A, Patel NC, Crismon ML (2004). Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
9. Der-Avakian A, Markou A (2012). The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 35:68-77.
10. Duman RS, Duric V, Banasr M, Adham N, Kiss B, Gyertyán I (2012). Cariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic unpredictable stress model of anhedonia. Neuropsychopharmacology 38 (S1):S84.
11. Dunlop BW, Nemeroff CB (2007). The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 64:327-337.
12. Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH, et al. (2010). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Washington, DC: American Psychiatric Association.
13. Gershon AA, Vishne T, Grunhaus L (2007). Dopamine D2-like receptors and the antidepressant response. Biol Psychiatry 61:145-153.
14. Graff-Guerrero A, Mamo D, Shammi CM, Mizrahi R, Marcon H, Barsoum P, et al. (2009). The effect of antipsychotics on the high-Affinity state of D2 and D3 receptors: A positron emission tomography study With [11C]-(+)-PHNO. Arch Gen Psychiatry 66:606-615.
15. Gross G, Drescher K (2012). The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol 213:167-210.
16. Gross G,Wicke K, Drescher KU (2013). Dopamine D3 receptor antagonism-still a therapeutic option for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol 386:155-166.
17. Gurevich EV, Joyce JN (1999). Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60-80.
18. Gyertyán I, Sághy K, Laszy J, Elekes O, Kedves R, Gémesi LI, et al. (2008). Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378:529-539.
19. Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, et al. (2011). Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 59:925-935.
20. Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU (2013). Second-generation antipsychotics in the treatment of major depressive disorder: Current evidence. Expert Rev Neurother 13:851-870.
21. Herbener ES, Harrow M (2002). The course of anhedonia during 10 years of schizophrenic illness. J Abnorm Psychol 111:237-248.
22. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
23. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr (1989). The Schedule for the Deficit syndrome: An instrument for research in schizophrenia. Psychiatry Res 30:119-123.
24. Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E, Bugovics G, et al. (2008). Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378:515-528.
25. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, et al. (2010). Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile. J Pharmacol Exp Ther 333:328-340.
26. Kiss B, Horti F, Bobok A (2012). Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res 136 (Suppl 1):S190.
27. Krishnan V, Nestler EJ (2011). Animal models of depression: Molecular perspectives. Curr Top Behav Neurosci 7:121-147.
28. Lammers CH, Diaz J, Schwartz JC, Sokoloff P (2000). Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 5:378-388.
29. Laszy J, Laszlovszky I, Gyertyán I (2005). Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl) 179:567-575.
30. Leggio GM, Micale V, Drago F (2008). Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST). Eur Neuropsychopharmacol 18:271-277.
31. Leggio GM, Salomone S, Bucolo C, Platania C, Micale V, Caraci F, Drago F (2013). Dopamine D(3) receptor as a new pharmacological target for the treatment of depression. Eur J Pharmacol 719:25-33.
32. Marston HM, Martin FD, Papp M, Gold L, Wong EH, Shahid M (2011). Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation. J Psychopharmacol 25:1388-1398.
33. McCormick PN, Wilson VS, Wilson AA, Remington GJ (2013). Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors. Pharmacol Res 70:66-71.
34. Millan MJ, Dekeyne A, Papp M, La Rochelle CD, MacSweeny C, Peglion JL, Brocco M (2001). S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:581-591.
35. Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, et al. (2011). Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res 131:63-68.
36. Monleon S, D'Aquila P, Parra A, Simon VM, Brain PF, Willner P (1995). Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology (Berl) 117:453-457.
37. Montgomery SA, Loft H, Sánchez C, Reines EH, Papp M (2001). Escitalopram (S-enantiomer of citalopram): Clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88:282-286.
38. Muñoz C, Papp M (1999). Alnespirone (S 20499), an agonist of 5-HT1A receptors, and imipramine have similar activity in a chronic mild stress model of depression. Pharmacol Biochem Behav 63:647-653.
39. Murray CJ, Lopez AD (1997). Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349:1436-1442.
40. Orsetti M, Canonico PL, Dellarole A, Colella L, Di Brisco F, Ghi P (2007). Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology 32:1783-1790.
41. Papp M (2012). Models of affective illness: Chronic mild stress in the rat. Curr Protoc Pharmacol Chapter 5:Unit 5.9.
42. Papp M, Moryl E, Willner P (1996). Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 296:129-136.
43. Pelizza L, Ferrari A (2009). Anhedonia in schizophrenia and major depression: State or trait? Ann Gen Psychiatry 8:22.
44. Richtand NM, Goldsmith RJ, Nolan JE, Berger SP (2001). The D3 dopamine receptor and substance dependence. J Addict Dis 20:19-32.
45. Richtand NM, Woods SC, Berger SP, Strakowski SM (2001). D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 25:427-443.
46. Shelton RC, Tomarken AJ (2001). Can recovery from depression be achieved? Psychiatr Serv 52:1469-1478.
47. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
48. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (2006). The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25-43.
49. Spijker J, Bijl RV, de Graaf R, Nolen WA (2001). Determinants of poor 1-year outcome of DSM-III-R major depression in the general population: Results of the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Acta Psychiatr Scand 103:122-130.
50. Strauss GP, Gold JM (2012). A new perspective on anhedonia in schizophrenia. Am J Psychiatry 169:364-373.
51. Treadway MT, Zald DH (2011). Reconsidering anhedonia in depression: Lessons from translational neuroscience. Neurosci Biobehav Rev 35:537-555.
52. Willner P (2005). Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52:90-110.
53. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R (1987). Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93:358-364.
54. Wise RA (2008). Dopamine and reward: The anhedonia hypothesis 30 years on. Neurotox Res 14:169-183.
55. Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, et al. (2005). Atypical antipsychotics in bipolar depression: Potential mechanisms of action. J Clin Psychiatry 66 (Suppl 5):40-48.
56. Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C (2013). Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 226:91-100.